BRD9 and Miyoshi myopathy: These selectively active concentrations of dBRD9a were comparable to, or higher than, combined concentrations shown in the present study to be synergistic for pomalidomide (75 nM)+ EA89 (BRD9 inhibitor) (750 nM) or pomalidomide (50 nM) + QA-68 (IMiD-based BRD9 degrader) (5 nM) against H929 MM cells, as shown in Figure 1B and Figure 1C, respectively.